miRNA in Colorectal Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Biomarkers".
Deadline for manuscript submissions: 30 November 2024 | Viewed by 1374
Special Issue Editor
Special Issue Information
Dear Colleagues,
Colorectal cancer represents a major health problem, being the third leading cause of death in developed countries. MicroRNAs (miRs) regulate gene activity post-transcriptionally through the inhibition of protein translation. In cancer, they can function as oncogenes or as tumor suppressors, and miR signatures can serve as promising biomarkers for diagnosis, prognosis, and treatment efficacy monitoring over the disease course. Recently, another class of small RNAs, the tRNA-derived small RNA (tsRNA), is generating increasing interest in cancer research. Transfer-RNA-derived small RNA reproduce miRNAs’ mechanisms of action by interacting with Argonaute (AGO) to inhibit protein translation. Both miRNAs and tsRNAs have been shown to play essential roles in malignant transformation, cell proliferation, migration and apoptosis. MicroRNAs and tsRNAs can be analyzed not only from solid tissues, but their small size and robustness in serum make them excellent candidates to be measured in fluids, including blood/plasma/serum, urine, or saliva. An accurate determination of miRNAs or tsRNAs in FFPE samples and, particularly, in biofluids, is complicated by their small size, high degree of homology, and need for their extraction. Therefore, these efforts require well-standardized and accurate procedures.
This Special Issue is dedicated to the following main topics in colorectal cancer:
- miRNAs or tsRNAs as diagnostic, prognostic and/or predictive biomarkers.
- Evaluation and comparison of different methodologies for accurate analysis of miRNAs and tsRNAs.
- Implications of miRNAs or tsRNAs in molecular mechanism studies carried out in cell lines or mouse models.
- Tumor subtyping based on miRNA or tsRNA expression analysis.
- The use of genomics and transcriptomics for the identification of novel miRNA/tsRNAs signatures.
We are pleased to invite you to contribute to this Special Issue with submissions of original research articles, reviews or metanalyses related to this subject.
Dr. Beatriz Perez-Villamil
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- colorectal cancer
- miRNAs
- tsRNAs
- molecular classification
- molecular mechanisms
- prognostic/predictive biomarkers
- genomics
- transcriptomics
